Joe Lieberman lit the tinder when he asked if HHS was making progress on "intravenous" antivirals, ie peramvir, and now BCRX is burning up the market up $1.60 on almost 5 million shares, and some projections of a billion dollars in revenue for a $300 mill market cap company. BIOCRYST on fire.